Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2021.62.455-6 3
Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases
Sandra Bašić-Kinda
; Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia
Karla Mišura Jakobac
; Division of Hematology, Department of Internal Medicine, University Hospital Merkur, Zagreb, Croatia
Jasminka Sinčić-Petričević
; Department of Hematology, Clinic of Internal Medicine, University Hospital Center, Osijek, Croatia
Dajana Deak
; Division of Hematology, Department of Internal Medicine, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia
Marijo Vodanović
; Division of Hematology, Department of Internal Medicine, University Hospital Merkur, Zagreb, Croatia
Marinka Jakić-Bubalo
; Division of Hematology, Department of Internal Medicine, University Hospital Center Split, Split, Croatia
Zdravko Mitrović
; Department of Internal Medicine, University of Zagreb, School of Medicine, Zagreb, Croatia
Barbara Dreta
; Division of Hematology, Department of Internal Medicine, University Hospital Center Split, Split, Croatia
Dubravka Županić Krmek
; Department of Internal Medicine, Sveti Duh University Hospital Center, Zagreb, Croatia
Božena Coha
; Department of Internal Medicine, Dr. Josip Benčević General Hospital, Slavonski Brod, Croatia
Delfa Radić Krišto
; Division of Hematology, Department of Internal Medicine, University Hospital Merkur, Zagreb, Croatia
Igor Aurer
orcid.org/0000-0001-6175-4277
; Department of Internal Medicine, University of Zagreb, School of Medicine, Zagreb, Croatia
Sažetak
Aim To compare the outcomes of Croatian patients with
mantle cell lymphoma (MCL) who started treatment in
2007 and 2008 (historical cohort) and of those who started
treatment between 2015 and 2017 (recent cohort).
Methods The historical cohort consisted of 40 patients
who started treatment with rituximab in 2007 and 2008.
Data on the recent cohort, consisting of 89 patients, were
collected retrospectively from the electronic databases of
Croatian hospitals with hematology units. Demographic
characteristics and data on induction regimens, autolo
-
gous stem cell transplantation (ASCT), and rituximab main
-
tenance in the first remission, event-free survival (EFS), and
overall survival (OS) were available for both cohorts, and
data on cell morphology, mantle cell international prog
-
nostic index (MIPI), and Ki67 expression only for the recent
cohort.
Results The recent cohort had significantly better twoyear EFS and OS (EFS 58% vs 40%, P=0.014; OS 80% vs 56%, P=0.009), especially in patients below 65. In univariate
analysis, induction regimen, ASCT, and maintenance were
significant prognostic factors for EFS and the former two
for OS. In the multivariate analysis, only ASCT remained
significant. Bendamustine
+rituximab (BR) induction im
-
proved the outcomes of non-transplantable patients over
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vin
-
cristine, steroid). Blastoid morphology and high MIPI were
adverse prognostic factors for EFS and OS.
Conclusion In the last decade, the outcome of newly di
-
agnosed MCL patients improved. ASCT in the first remis
-
sion was the main contributor in transplantable patients
and BR in non-transplantable. Regularly updated nation
-
al guidelines may help in a timely adoption of new treat
-
ments, thus improving the results.
Ključne riječi
Hrčak ID:
278466
URI
Datum izdavanja:
21.10.2021.
Posjeta: 462 *